<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123885</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI163</org_study_id>
    <nct_id>NCT05123885</nct_id>
  </id_info>
  <brief_title>Wearable Then Implantable Cardiac Defibrillator After Myocardial Infarction</brief_title>
  <acronym>WICD-MI</acronym>
  <official_title>Impact Pronostique d'un événement Rythmique Ventriculaire Durant le Port de la LifeVest en Post-infarctus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sudden death from ventricular arrhythmia is a serious and common complication of myocardial&#xD;
      infarction, especially with low left ventricular ejection fraction (LVEF). Implantable&#xD;
      cardiac defibrillator (ICD) implantation is currently recommended at three months of optimal&#xD;
      medical treatment in patients who have had a myocardial infarction and have a LVEF below 35%.&#xD;
      This strategy indeed allows a reduction in mortality while early post-infarction implantation&#xD;
      showed no benefit in terms of survival. However, the risk of sudden death at this period is&#xD;
      the greatest and the temporary defibrillator vest, marketed under the name LifeVest, is now&#xD;
      indicated in the early post-infarction period in patients with LVEF less than 35%. Indeed,&#xD;
      the LifeVest would allow a reduction in sudden death of rhythmic origin in the first three&#xD;
      months post-infarction. No study has yet investigated the prognostic significance of a&#xD;
      ventricular rhythm disorder (ventricular tachycardia [VT] or ventricular fibrillation [VF])&#xD;
      occurring during this early and short (approximately 3 months) particular period of wearing&#xD;
      the LifeVest: is this a random event, or is it an event predictive of a rhythmic recurrence?&#xD;
      The aim of the study is to assess the association between the occurrence of a sustained&#xD;
      ventricular rhythm disorder in the early post-infarction period, during the period of wearing&#xD;
      the LifeVest (ventricular episodes detected, treated or not), and the risk of rhythmic&#xD;
      recurrence at 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.</measure>
    <time_frame>12 months after ICD implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.</measure>
    <time_frame>Up to 7 years after ICD implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmic storm defined by ACC / AHA / ESC 2006 guidelines (≥3 episodes of VF, sustained VT or appropriate shock in 24 hours).</measure>
    <time_frame>12 months and up to 7 years after ICD implantation]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need to set-up left ventricular assist device (LVAD) or heart transplantation.</measure>
    <time_frame>: 12 months and up to 7 years after ICD implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death.</measure>
    <time_frame>12 months and up to 7 years after ICD implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure worsening.</measure>
    <time_frame>12 months and up to 7 years after ICD implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD, and mortality from any cause.</measure>
    <time_frame>Frame: 12 months and up to 7 years after ICD implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD, and mortality from any cause.</measure>
    <time_frame>12 months and up to 7 years after ICD implantation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Infarction, Myocardial</condition>
  <arm_group>
    <arm_group_label>Experimental:</arm_group_label>
    <description>Adult patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest after a myocardial infarction, followed by the implantation of an ICD before March 1, 2021.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study on Data</intervention_name>
    <description>Study on Data</description>
    <arm_group_label>Experimental:</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest&#xD;
        after a myocardial infarction, followed by the implantation of an ICD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients who benefited, between the start of 2015 and January 1, 2021, from a&#xD;
             LifeVest after a myocardial infarction, followed by the implantation of an ICD before&#xD;
             March 1, 2021.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient opposition to the use of their data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu ECHIVARD, MD, PhD</last_name>
    <phone>+ 33383157356</phone>
    <phone_ext>+33</phone_ext>
    <email>m.echivard@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas GIRERD, MD, PhD</last_name>
    <phone>+33383157322</phone>
    <phone_ext>+33</phone_ext>
    <email>n.girerd@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Bordeaux Pessac</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre BORDACHAR, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre BORDACHAR, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain ESCHALIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain ESCHALIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clémence DOCQ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clémence DOCQ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Aphm Marseille La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Baptiste MAILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Baptiste MAILLE MAILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Luc PASQUIER, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Luc PASQUIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien MINOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Damien MINOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Php Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eloi MARIJON, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eloi MARIJON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Raphaël MARTINS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raphaël MARTINS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Aphp Salpetriere</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Estelle GANDJBAKHCH, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Estelle GANDJBAKHCH, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Cardiologique Du Nord Saint-Denis</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier PIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier PIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine DA COSTA, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine DA COSTA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre MONDOLY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre MONDOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Serge BOVEDA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Serge BOVEDA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tours Saint-Avertin</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu ECHIVARD, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu ECHIVARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

